Johnson and Johnson (JNJ) 시세

Potential Acquisition of MindMed by J&J or Similar Pharma Companies:

Given Johnson & Johnson’s (J&J) recent acquisition of Intra-Cellular Therapies (ITCI) and its Phase 2 asset for Generalized Anxiety Disorder (GAD), the possibility of J&J or another major pharmaceutical company acquiring MindMed is a realistic scenario.
Why MindMed is an Attractive Acquisition Target

Psychedelic-Based Innovation – MindMed’s MM-120 (LSD-derived treatment) represents a novel approach to GAD that could complement or even disrupt traditional pharmacological treatments. Major pharma companies, including J&J, have been exploring psychedelic-based treatments, evidenced by their previous work with Spravato (esketamine) for depression.

Regulatory Progress and Phase 3 Trials – MM-120 is already in Phase 3 clinical trials and has received Breakthrough Therapy Designation from the FDA. A successful Phase 3 outcome would make MindMed a highly attractive buyout target, as acquiring a late-stage asset could be more efficient than developing a new one in-house.

Market Differentiation – J&J’s acquisition of ITCI suggests they are seeking broader control over the GAD treatment market. However, ITI-1284 operates through a traditional neuropsychiatric mechanism, whereas MM-120 offers a radically different approach via serotonergic psychedelics. This divergence could make MM-120 a highly valuable asset for any pharma company looking to hedge their neuroscience portfolio with a potentially revolutionary treatment.

Big Pharma’s Need for Pipeline Expansion – Large pharmaceutical companies, including J&J, Pfizer, and Merck, are continuously searching for promising late-stage clinical assets to maintain revenue streams as existing drug patents expire. The psychedelic medicine space is emerging as a major area of interest, especially as more clinical data supports the long-term efficacy and safety of these compounds.

Challenges and Considerations

Regulatory Uncertainty – Despite promising trial results, psychedelic-based therapies still face regulatory hurdles and stigma. J&J or another major pharma company may wait until MM-120 secures full FDA approval before making a move.

Cultural Fit and Integration – MindMed is structured as a high-risk, high-reward biotech firm focusing on psychedelic medicine. A large pharmaceutical company might hesitate to fully integrate this approach into a more traditional CNS pipeline.

Competition from Other Pharma Companies – While J&J could be a strong contender to acquire MindMed, other companies with neuroscience portfolios (e.g., AbbVie, Novartis, or Biogen) could also see MM-120 as an opportunity to expand into the psychedelic treatment space.

Conclusion: Likelihood of Acquisition

A J&J acquisition of MindMed is not out of the question, especially given J&J’s ongoing commitment to CNS treatments and GAD. However, whether J&J makes a move could depend on:

The success of MM-120’s Phase 3 trials
Market receptiveness to psychedelic-based treatments
Competitive interest from other pharmaceutical giants

If MM-120 demonstrates clear clinical efficacy and FDA approval seems likely, MindMed will almost certainly become a prime acquisition target in the next 12–24 months. J&J, given its recent neuroscience expansion, could be a logical suitor, but other pharma companies in the CNS space could also enter the fray, making a competitive bidding scenario plausible.

JNJ, 10q due 1/22

Oddly since posting this MindMed is looking at JNJ Spravato clinics to commercialize their MM-120 drug once FDA approved.

I bet they scoop them up.

Look at their last company presentation.

Seen that hoping JNJ (or someone) buying MNMD... We are getting close to some interesting acquisitions in this space.

Correction: $14.6 billion.

JNJ buys ITCI for ~ 4.8 Billion.

Johnson & Johnson $JNJ Total Debt (mrq) $35.75B

J&J has been involved in psychiatric drug development for decades and might be interested in psychedelic therapies as a way to differentiate their mental health offerings. J&J's Janssen division has explored the use of psychedelic compounds, such as in their work with esketamine (Spravato), a nasal spray approved for treatment-resistant depression. This makes J&J a potential acquirer for MindMed if the company wants to delve further into psychedelic-based treatments.

Thoughts on that?

imo... when my blonde haired comb over fat hero put the CEO of this pos out there to address the masses pushing vaccines.... I thought maybe he was playing th'old 4D Chess move.... they did not know I was playing 5D.


JNJ



IHuser

JNJ 10Q due OCTOBER 15

DNFWM........I am Christ and and I will cast you to hell if you fuck with me period~

JNJ 10Q due JULY17

https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm

JNJ 10Q due 4/16

$JNJ has Total Debt (mrq) $29.92B

imo..... i have toppled bf starting w the evil worthless king flying red bull ace....those paying attention have watched in dismay...next!


JNJ PFE

IHuser

imo... this ticker is a toxic POS...FOLOW MY GROUP at PFE....


IHuser

imo...my global following will crash this stock.....and me....JNJ

imo.... if you are bullish on this ticker i will ruin you and your whole life....f with me JNJ


IHuser

JNJ’s KVUE spin-off now has its own iHub board:

https://investorshub.advfn.com/Kenvue-Inc-KVUE-42070

anyone here, read about enzolytics pharm announcing the now have a cure for hiv/aids called clone 3 yesterday.

Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer (8/21/23)

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Under the terms of the exchange offer, 8.0324 shares of Kenvue common stock will be exchanged for each share of Johnson & Johnson common stock accepted in the exchange offer.

According to the exchange agent, Computershare Trust Company, N.A., 802,707,331 shares of Johnson & Johnson common stock were validly tendered and not validly withdrawn, including 250,407,279 shares that were tendered by notice of guaranteed delivery. Johnson & Johnson intends to accept 190,955,436 of the tendered shares in exchange for the 1,533,830,450 shares of Kenvue common stock owned by Johnson & Johnson. Because the exchange offer was oversubscribed, Johnson & Johnson is accepting only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Johnson & Johnson common stock, or an "odd-lot," who have validly tendered all of their shares, will not be subject to proration, in accordance with the terms of the exchange offer.

Based on the total number of shares of Johnson & Johnson common stock reported to be tendered prior to the expiration of the exchange offer, it is estimated that approximately 23.8% of the tendered shares of Johnson & Johnson common stock will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures, as well as the number of "odd-lot" shares that were validly tendered and are not subject to proration. Johnson & Johnson expects to announce the final proration factor on August 23, 2023, promptly following the expiration of the guaranteed delivery period. Shares of Johnson & Johnson common stock tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly after the final proration factor is announced. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the dealer managers for the exchange offer.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

https://www.businesswire.com/news/home/20230821033927/en/Johnson-Johnson-Announces-Preliminary-Results-of-Kenvue-Inc.-Exchange-Offer

The Final Exchange Ratio is 8.0324 shares of KVUE per JNJ share (unless extended).

https://www.sec.gov/Archives/edgar/data/200406/000162828023029851/vwapday19.htm

imo... this ticker is culpable as any poisoning people...JNJ










IHuser

Type in a symbol by mistake and came up with this stock

Type in a symbol by mistake and came up with this stock

Nice long run

And.....?

Bankruptcy judge tosses JNJ’s proposed talc settlement:

https://www.wsj.com/articles/johnson-johnsons-second-talc-bankruptcy-case-thrown-out-74a63a13 A New Jersey bankruptcy judge threw out the second chapter 11 case that Johnson & Johnson filed to resolve its mass talc liabilities, again shutting down the healthcare-product company’s plan to achieve an $8.9 billion settlement [see #msg-171617699].

Judge Michael Kaplan of the U.S. Bankruptcy Court in Trenton, N.J., said that J&J affiliate LTL Management LLC, created to carry the company’s talc-related liabilities into bankruptcy, wasn’t in sufficient financial distress to warrant granting it the legal protections of chapter 11.

JNJ launches tax-free exchange offer for KVUE:

https://www.businesswire.com/news/home/20230723805654/en

J&J Vaccine and Guillain-Barré Syndrome: Information on the FDA Warning
https://www.yalemedicine.org/news/covid-vaccine-guillain-barre-syndrome $JNJ

Johnson & Johnson $JNJ Total Debt (mrq) $52.91B

***US FDA Revokes Emergency Use Authorization of J&J COVID-19 Vaccine***

***serious risk of blood clots***

TOO MANY DEAD PEOPLE.... JNJ KILLED TO MANY PATIENTS WITH THIS EXPERIMENTAL VACCINE POISON THAT HAD NO LONG TERM SAFETY TESTING!!!!!!

JNJ IS LIABLE FOR KILLING ALL THOSE INNOCENT PEOPLE!!!!!!

THESE CRIMINALS WILL BE SUED INTO OBLIVION!!!!!!!

SHORT THIS RANCID STOCK!!!!!!!!!

BMY/JNJ—Milvexian—>FDA Fast Track designation for_all_phase-3_indications:

https://finance.yahoo.com/news/milvexian-granted-u-fda-fast-105900364.html

The three Milvexian indications BMY/JNJ are pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF—see #msg-171338375.

FDA Fast Track status doesn’t mean much, but it makes a Priority Review of the NDAs somewhat more likely (if one or more of these phase-3 trials pan out).

Please see #msg-169818942 for additional background info.

p.s. This PR was issued yesterday.

JNJ’s talc settlement encounters a hitch:

https://endpts.com/talc-claimants-look-to-sue-jj-over-alleged-fraud-in-bankruptcy-case/

KVUE +22% on_first_day_of_trading, valuing_the_company_at ~$50B.

JNJ consumer spinoff, Kenvue IPOs @$22.00—starts_trading_today_as KVUE:

https://finance.yahoo.com/news/kenvue-begin-trading-york-stock-132500217.html

At the IPO price, KVUE’s market cap is ~$41B. Following the IPO, JNJ still owns about 90% of KVUE and plans to distribute the remainder to JNJ shareholders at some point.

Caution: KVUE bears 100% of JNJ’s talc liability outside of the US and Canada.

Holding Big Pharma ACCOUNTABLE: J & J To Pay Victims $8.9 Billion For Cancer Causing Baby Powder!!!!!

WHAT KIND OF MONSTERS RUN J & J?????

SMEARING CANCER ON BABIES???????

SHORT THIS CRAP TO OBLIVION!!!!!!!

Addendum—JNJ’s ex-North America talc liabilities are being transferred to the Kenvue spinoff, according to Kenvue’s SEC filings.

JNJ asserts_it_has_settled_North_America talc claims_for_an NPV_of_$8.9B_spread_over_25_years:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000200406/000020040623000037/jnj-20230404.htm On April 4, 2023, the Company announced that its wholly owned subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will efficiently resolve all current and future claims arising from cosmetic talc litigation against the Company and its affiliates in North America. The Company has agreed to contribute up to the present value of $8.9 billion over 25 years (nominal value approximately $12 billion) to resolve the North America talc claims… JNJ’s press release (https://www.sec.gov/Archives/edgar/data/200406/000020040623000037/a44238-kexhibit991.htm ) says: LTL also has secured commitments from over 60,000 current claimants to support a global resolution on these terms. Notably, the PR doesn’t say how many other ex-North America claimants there are (or will be) and what is meant by the phrase, “these terms.”

JNJ has earmarked $61.5B for talc liability, according to court documents:

https://www.fiercepharma.com/pharma/after-johnson-johnson-loses-again-bankruptcy-case-its-game-talc-lawsuits

imo...Mr. Putin and the white hat US are dropping these criminals...thank-you..from USA___JNJ

Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits https://www.rttnews.com/3340418/court-rejects-j-j-bankruptcy-petition-to-end-talc-cancer-lawsuits.aspx $JNJ

Whoops better start digging in the cushions for some change J&J!

$JNJ Book Value only $28.51

$JNJ has $32.03B DEBT

imo...no posts....yal want me to post godsmack....ok.......ready____JNJ

imo...

imo...